Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View.
COVID-19
Hospital Information System (HIS)
Treatment Strategies
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
3
12
2020
Statut:
ppublish
Résumé
The Coronavirus disease 2019 (COVID-19) outbreak quickly has spread and became a pandemic. However, no approved therapeutics or effective treatment is available for the treatment of these patients. The present study was done to retrospectively assess the treatment strategies (e.g., pharmaceutical care services) for COVID-19 patients in selected hospitals and highlight the importance of such services in the management of a pandemic. Data from a series of COVID-19 patients (978 patients; 658 males [66.9%] and 324 females [33.1%]) admitted to the selected hospitals in Tehran from 20 February to 19 March 2020 were retrieved retrospectively from the Health Information System (HIS) of the hospitals. The statistical tests were used for analyzing the effect and correlation of the variables (drugs) with the average length of stay (ALOS) in the hospital. Diverse medication classes and old drugs with or without strong evidence of therapeutic effects against the novel coronavirus, some previously tried as a treatment for SARS-CoV and MERS-CoV, were mostly used for the treatment of patients in the hospitals. Many medications (broad-spectrum antibiotics and antivirals) or combination therapies are used without evidence of their therapeutic effects during pandemics. Therefore, guidelines should be provided for the off-label use of these drugs by policymakers and stakeholders during a pandemic emergency due to high demands. Also, monitoring of the HIS data can play an important role in improving public health response to emerging diseases.
Sections du résumé
BACKGROUND
BACKGROUND
The Coronavirus disease 2019 (COVID-19) outbreak quickly has spread and became a pandemic. However, no approved therapeutics or effective treatment is available for the treatment of these patients. The present study was done to retrospectively assess the treatment strategies (e.g., pharmaceutical care services) for COVID-19 patients in selected hospitals and highlight the importance of such services in the management of a pandemic.
MATERIALS AND METHODS
METHODS
Data from a series of COVID-19 patients (978 patients; 658 males [66.9%] and 324 females [33.1%]) admitted to the selected hospitals in Tehran from 20 February to 19 March 2020 were retrieved retrospectively from the Health Information System (HIS) of the hospitals. The statistical tests were used for analyzing the effect and correlation of the variables (drugs) with the average length of stay (ALOS) in the hospital.
RESULTS
RESULTS
Diverse medication classes and old drugs with or without strong evidence of therapeutic effects against the novel coronavirus, some previously tried as a treatment for SARS-CoV and MERS-CoV, were mostly used for the treatment of patients in the hospitals. Many medications (broad-spectrum antibiotics and antivirals) or combination therapies are used without evidence of their therapeutic effects during pandemics.
CONCLUSION
CONCLUSIONS
Therefore, guidelines should be provided for the off-label use of these drugs by policymakers and stakeholders during a pandemic emergency due to high demands. Also, monitoring of the HIS data can play an important role in improving public health response to emerging diseases.
Types de publication
Journal Article
Langues
eng
Pagination
112-121Informations de copyright
Copyright© 2020 National Research Institute of Tuberculosis and Lung Disease.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Antivir Chem Chemother. 2006;17(5):275-84
pubmed: 17176632
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Int J Antimicrob Agents. 2007 Oct;30(4):297-308
pubmed: 17629679
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283154
Am J Obstet Gynecol. 2020 Jun;222(6):639-640
pubmed: 32017921
Lancet. 2018 Jul 7;392(10141):75-87
pubmed: 29937192
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Brain Behav Immun. 2020 Jul;87:59-73
pubmed: 32334062
HeartRhythm Case Rep. 2020 Apr 01;6(5):244-248
pubmed: 32363145
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Nat Med. 2020 Apr;26(4):465
pubmed: 32273604
J Interferon Cytokine Res. 2015 Mar;35(3):143-56
pubmed: 25321315
Virol Sin. 2020 Jun;35(3):266-271
pubmed: 32125642
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
J Am Coll Cardiol. 2020 Jun 16;75(23):2992-2993
pubmed: 32330546
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Arch Med Res. 2020 May;51(4):347-348
pubmed: 32340759
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Antimicrob Agents Chemother. 2020 Apr 21;64(5):
pubmed: 32152082
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
HeartRhythm Case Rep. 2020 Apr 01;6(5):241-243
pubmed: 32363144
J Med Chem. 2006 May 4;49(9):2845-9
pubmed: 16640347